Tolvaptan vs Fluid Restriction in Moderate-Profound Hyponatremia: An Open-Label Randomized Clinical Trial.

J Clin Endocrinol Metab · 2026 · PMC12819845 · PMID 40720585

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendP = .06so close (0.05 < p ≤ 0.1)

Post hoc exploratory analysis in the subset of participants with a length of stay less than 10 days (N = 20) showed a trend toward reduced length of stay with tolvaptan (5.0 days [IQR 4.3-5.8] vs 6.5 days [IQR 5.3-7.0]; P = .06).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.